A paper published this month in Annals of Clinical and Translational Neurology adds a new entry to the very short published record on FARS2. More usefully for research, it doesn't just describe a case — it measures what two specific changes in the gene actually do to the protein the gene builds.
What FARS2 does in the first place
Mitochondria are the compartments inside our cells that generate most of our energy. They build a small set of their own proteins, and to do that they need a delivery system: every amino acid (the building blocks proteins are made from) has to be clipped onto a matching carrier molecule before it can be used. FARS2 holds the instructions for the enzyme that performs one specific clip: attaching the amino acid phenylalanine to its carrier. When that enzyme works less efficiently, mitochondrial protein production runs below full speed.
What the researchers found
The team sequenced a child and both parents together — a "trio" — which makes it much easier to tell which change came from which side. They found two different changes in the gene, one inherited from each parent:
Q216X, from the father — a "stop" signal introduced roughly halfway along, so the enzyme gets cut short and never receives the working parts it needs.
P136H, from the mother — a single building block swapped for another, in a stretch of the protein that has stayed nearly identical across very different species. Nature tends to conserve the parts that matter, so that location was a clue.
The researchers then made both versions of the protein in the lab and tested them directly. The shortened version couldn't even be produced in usable form. The P136H version, though, still worked — just not at full strength. It kept partial activity.
Partial activity is not the same as no activity — and that distinction is one of the most useful things in this paper.
An enzyme that still functions at reduced capacity is a very different research target than one that is missing entirely. It leaves something for a future therapy to work with.
The brain imaging was the paper's other contribution. MRI showed matching signal changes on both sides in the dentate nuclei, a pair of structures tucked into the cerebellum at the back and base of the brain. That pattern hadn't been flagged in FARS2 before, although it had shown up in a report on SARS2, a closely related gene. Adding it to the list of things radiologists know to look for makes FARS2 easier to recognise.
That's the broader value here. FARS2 had mostly been described in a fairly narrow set of circumstances, and this case sat at a different point on the range — motor symptoms affecting the legs, without the seizures or cognitive changes reported elsewhere. Widening the recognised picture is what gets a gene tested for, rather than ruled out early.
Read the full paper (open access): https://pmc.ncbi.nlm.nih.gov/articles/PMC6144452/